By Nana O 
A groundbreaking study led by researchers at NYU Langone Health and its Perlmutter Cancer Center has unveiled a powerful new tool in the fight against melanoma: monitoring blood levels of circulating tumor DNA (ctDNA) can accurately predict the recurrence of skin cancer, particularly in patients with stage III melanoma. This innovative approach, detailed in the April 15th online publication of The Lancet Oncology, offers a significant advancement in early detection and personalized treatment strategies for one of the deadliest forms of skin cancer.
Unlocking the Secrets of ctDNA in Melanoma Recurrence
The study, which represents the largest assessment to date of ctDNA as a recurrence predictor in stage III melanoma, involved nearly 600 men and women who had previously participated in a clinical trial for this stage of the disease. Researchers analyzed blood samples from participants across Europe, North America, and Australia, comparing ctDNA measurements with clinical evidence of cancer recurrence. The findings indicate a strong correlation: approximately 80% of stage III melanoma patients who exhibited detectable levels of ctDNA before initiating treatment to suppress their tumors subsequently experienced recurrence.
This detectable presence of ctDNA before treatment commencement served as a potent warning sign. Furthermore, the study revealed a stark difference in recurrence speed: individuals with detectable ctDNA saw their disease return more than four times faster than those with undetectable levels. The intensity of the ctDNA signal also correlated with the speed of recurrence, with higher levels indicating a more aggressive and rapid return of the cancer.
"Our findings suggest that circulating tumor DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy," stated Mahrukh Syeda, MS, the study’s lead author and a research scientist in the Ronald O. Perlman Department of Dermatology at NYU Grossman School of Medicine. "In the future, such assessments may be used routinely in the clinic to help guide treatment decisions."
A New Frontier in Early Detection
The implications of this research extend to the critical period during treatment. The team discovered that nearly all patients with detectable ctDNA levels at three, six, nine, or twelve months into their treatment regimen experienced melanoma recurrence. This suggests that even if ctDNA is not observable prior to therapy, its emergence during treatment could signal a worsening of the disease, potentially prompting oncologists to reassess treatment plans or consider alternative therapeutic approaches.
Stage III melanoma is characterized by the spread of tumor cells from the skin to nearby lymph nodes. Following surgical removal of these affected lymph nodes, detecting residual cancer or early signs of recurrence can be challenging with conventional imaging methods such as X-rays and CT scans. This diagnostic gap has fueled the urgent search for more sensitive and accurate methods for early cancer detection.
"Swiftly tracking treatment progress and the ability to spot signs of cancer growth could be helpful in a disease as dangerous as melanoma, which is notoriously difficult to treat once it spreads to other body parts," explained Syeda. "Early feedback from a ctDNA analysis might save lives."
The Science Behind the Breakthrough
The ctDNA method operates by targeting common mutations found in the genetic code of melanoma cells. As tumor cells break down, fragments of this mutated DNA are released into the bloodstream, where they can be detected and quantified. This "liquid biopsy" approach offers a less invasive alternative to traditional tissue biopsies and provides a real-time snapshot of the disease’s presence and activity.
This is not the first time ctDNA has shown promise in cancer detection. Previous research has established its efficacy in tracing the progression of other cancers, including colorectal and breast cancers. Building upon this foundation, the same research team previously found in 2021 that elevated ctDNA levels in patients with stage IV melanoma (which has metastasized throughout the body) were associated with poorer survival outcomes. They also demonstrated that changes in ctDNA measurements during treatment could predict patient survival chances.
Rigorous Methodology and Promising Comparisons
The latest investigation’s robustness is underscored by its large sample size and comprehensive statistical analysis. The research team meticulously accounted for various factors that could influence recurrence, including patient sex, age, and the specific type of therapy received. This rigorous approach ensures that the observed correlations between ctDNA levels and recurrence are as accurate as possible.
Significantly, the study found that assessing ctDNA levels was as effective, and in some cases superior, to other experimental tests that examine the tumor itself, such as those measuring immune activity within cancer cell clusters. This comparison highlights the direct and potent predictive power of ctDNA.
"Unlike standard, tissue-based analyses of tumor cells, which can only suggest the likelihood of recurrence, circulating tumor DNA tests provide a clear, direct measure of the disease itself and can tell us outright that melanoma has returned," emphasized study senior author and dermatologist David Polsky, MD, PhD. Dr. Polsky holds the Alfred W. Kopf, M.D., Professorship of Dermatologic Oncology in the Ronald O. Perelman Department of Dermatology and is also a professor in NYU Grossman School of Medicine’s Department of Pathology.
Addressing Limitations and Future Directions
While the study presents compelling evidence, the researchers acknowledge that ctDNA testing is not infallible. Dr. Polsky cautioned that in a subset of cases, cancer recurred even in patients who had a negative ctDNA test result prior to initiating therapy. This finding underscores the ongoing need for refinement and improvement in diagnostic technologies.
To address this limitation, the research team has outlined future research priorities. They plan to focus on enhancing the sensitivity of their ctDNA test to capture even lower levels of circulating tumor DNA. Furthermore, they intend to conduct clinical trials to rigorously evaluate whether incorporating ctDNA-guided treatment decisions can demonstrably improve patient survival rates and overall quality of life. This marks a crucial step towards integrating this promising biomarker into routine clinical practice.
Broader Implications for Cancer Care
The implications of this research extend beyond melanoma. The successful application of ctDNA monitoring in stage III melanoma suggests a potential paradigm shift in how various cancers are managed. The ability to detect recurrence early, monitor treatment response, and potentially guide therapeutic adjustments non-invasively could revolutionize cancer care, leading to more personalized and effective treatment strategies.
The financial support for this study was provided by Novartis Pharmaceuticals Corporation. Several researchers from Novartis Pharmaceuticals Corporation and Novartis Healthcare Pvt. Ltd. were involved in the study, alongside investigators from leading academic institutions worldwide, including the University of Sydney, the University of Queensland, the National Cancer Institute of Milan, the University of Duisburg-Essen, the University Hospital Campus Kiel, the University of Western Australia, the University of Perugia, the Veneto Institute of Oncology, the Cross Cancer Institute, St. Petersburg Oncology Hospital, and the University Hospital Zurich Skin Cancer Center.
The collaborative nature of this international research effort underscores the global commitment to advancing cancer diagnostics and treatment. The detailed disclosure of potential conflicts of interest by Dr. Polsky, including his advisory roles and financial relationships with pharmaceutical companies, adheres to ethical guidelines and ensures transparency in scientific reporting. These relationships are managed in accordance with NYU Langone Health’s policies and procedures.
The combined expertise of researchers from diverse geographical locations and institutions, including Jennifer Wiggins-Crosby, PhD, and Saim Ali, BA from NYU Langone Health, along with a distinguished international team of oncologists and scientists, has been instrumental in bringing this significant finding to light. Their collective efforts are paving the way for a future where liquid biopsies play a central role in the fight against cancer.
